Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print April 20, 2005, doi:10.1212/01.WNL.0000162031.03390.BA)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 64, Number 10, May 24, 2005
Right arrow Polish Data Supplement
Right arrow All Versions of this Article:
01.WNL.0000162031.03390.BAv1
64/10/1768    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pellock, J. M.
Right arrow Articles by Shinnar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pellock, J. M.
Right arrow Articles by Shinnar, S.
Related Collections
Right arrow All Pediatric
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
NEUROLOGY 2005;64:1768-1770
© 2005 American Academy of Neurology
Brief Communications

Respiratory adverse events associated with diazepam rectal gel

John M. Pellock, MD and Shlomo Shinnar, MD, PhD

From the Departments of Neurology, Pediatrics, Pharmacy, and Pharmaceutics (Dr. Pellock), Virginia Commonwealth University, Medical College of Virginia, Richmond; and Departments of Neurology, Pediatrics, and the Comprehensive Epilepsy Management Center (Dr. Shinnar), Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY.

Address correspondence and reprint requests to Dr. John M. Pellock, Division of Child Neurology, Virginia Commonwealth University, PO Box 980211, Children’s Pavilion, First Floor, Richmond, VA 23298-0211; e-mail: jpellock{at}hsc.vcu.edu

The authors reviewed respiratory adverse events and deaths spontaneously reported to Xcel Pharmaceuticals associated with diazepam rectal gel. Over 2 million doses have been prescribed. The authors identified nine respiratory adverse events and three deaths. The respiratory events associated with prolonged seizures had a good outcome. The deaths occurred in the context of a prolonged seizure and respiratory depression was not the main symptom. When used as recommended, diazepam rectal gel has a low rate of serious morbidity or mortality.

Funded by Xcel Pharmaceuticals.

Drs. Pellock and Shinnar are consultants to Xcel Pharmaceuticals, the manufacturer of Diastat, and received personal compensation to review the adverse events of rectal diazepam gel registered through MedWatch, analyze the data, and prepare the manuscript. Drs. Pellock and Shinnar have received grants and honoraria in excess of $10,000 from Xcel Pharmaceuticals.

Received June 28, 2004. Accepted in final form January 27, 2005.




This article has been cited by other articles:


Home page
 PediatricsHome page
Steering Committee on Quality Improvement and Mana
Febrile Seizures: Clinical Practice Guideline for the Long-term Management of the Child With Simple Febrile Seizures
Pediatrics, June 1, 2008; 121(6): 1281 - 1286.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.